Related Experiment Videos
Evaluation of ceforanide as treatment for staphylococcal and streptococcal endocarditis
Abstract:
Ceforanide administered parenterally twice daily was used as the sole agent to treat 17 patients with right-sided endocarditis due to Staphylococcus aureus or nonenterococcal streptococci. Fifteen patients were cured of their original infection. Two patients were withdrawn from the study. One patient was transferred to another hospital 4 days after ceforanide therapy was initiated, and the other was changed to a different antibiotic regimen when his viridans streptococcus proved tolerant to ceforanide. The intramuscular form of ceforanide was well tolerated. It was stopped in two patients after week 3 of therapy because of adverse effects, possibly related to the study drug. These findings resolved with discontinuation of the ceforanide, and no additional antimicrobial therapy was necessary. Two patients who continued to abuse drugs intravenously during the study developed bacteremia with new organisms and required additional antimicrobial therapy. Ceforanide proved to be a useful agent in the treatment of right-sided endocarditis due to susceptible S. aureus and nonenterococcal streptococci.
Insights
Ceforanide effectively treated right-sided endocarditis in most patients infected with Staphylococcus aureus or streptococci. This antibiotic demonstrated good tolerance and efficacy for susceptible bacterial infections.
Area of Science:
- Infectious Diseases
- Cardiology
- Pharmacology
Background:
- Right-sided endocarditis is a serious infection affecting heart valves.
- Staphylococcus aureus and nonenterococcal streptococci are common causative agents.
- Parenteral antibiotic therapy is the standard treatment approach.
Purpose of the Study:
- To evaluate the efficacy and tolerability of ceforanide as a sole agent for treating right-sided endocarditis.
- To assess treatment outcomes in patients with Staphylococcus aureus or nonenterococcal streptococci infections.
Main Methods:
- A study involving 17 patients with right-sided endocarditis.
- Ceforanide administered parenterally twice daily as the primary treatment.
- Monitoring for treatment efficacy, adverse effects, and patient outcomes.
Main Results:
- Fifteen out of 17 patients were cured of their initial infection.
- Ceforanide was generally well tolerated, with adverse effects resolving upon discontinuation.
- Two patients required additional therapy due to new bacteremia from intravenous drug abuse.
Conclusions:
- Ceforanide is a useful therapeutic option for right-sided endocarditis caused by susceptible Staphylococcus aureus and nonenterococcal streptococci.
- The intramuscular formulation of ceforanide demonstrated good tolerability in the studied patient group.